Abstract
Background: Alzheimer’s disease (AD) is the most common neurodegenerative disease, and the accumulation of amyloid-β is the initial process in AD. MicroRNAs (miRNAs) are widely known as key regulators of the accumulation of amyloid-β in AD. This study analyzed the potential effects and possible internal mechanisms of miR-340 on AD.
Methods: The expression of miR-340 in senescence-accelerated mouse prone-8 (SAMP8) mouse and senescence-accelerated mice/resistant-1 (SAMR1) mouse was evaluated by qRT-PCR (quantitative real-time polymerase chain reaction). The expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) was determined by qRT-PCR and western blot. The binding ability between miR-340 and BACE1 was verified by dual-luciferase reporter assay. In vitro cell model of AD was established in human neuroblastoma SH-SY5Y cells transfected with Swedish mutant form of amyloid precursor protein (APPswe). The effect of miR-340 on the accumulation of amyloid- β was investigated by western blot analysis. Flow cytometry was conducted to detect cell apoptosis.
Results: MiR-340 was down-regulated in the hippocampus of AD model SAMP8 mouse compared to SAMR1 mouse, while BACE1 was up-regulated in SAMP8, suggesting a negative correlation between miR-340 and BACE1 in SAMP8 mouse. MiR-340 could directly bind with BACE1, and over-expression of miR-340 decreased expression of BACE1 in SH-SY5Y/APPswe cells. MiR- 340 reduced the accumulation of amyloid-β and suppressed cell apoptosis through targeting BACE1 in SH-SY5Y/APPswe cells.
Conclusion: MiR-340 was downregulated in AD and reduced the accumulation of amyloid-β through targeting BACE1, suggesting a potential therapeutic target for AD.
Keywords: miR-340, BACE1, amyloid-β, Alzheimer's disease, amyloid precursor protein (APPswe), neuronal cell.
[http://dx.doi.org/10.1038/nature02621] [PMID: 15295589]
[PMID: 31091848]
[http://dx.doi.org/10.1016/j.envres.2017.05.011] [PMID: 28511080]
[http://dx.doi.org/10.31083/j.jin.2019.03.1105] [PMID: 31601083]
[http://dx.doi.org/10.31083/j.jin.2019.03.168] [PMID: 31601081]
[http://dx.doi.org/10.1152/physrev.00023.2009] [PMID: 20393191]
[http://dx.doi.org/10.2174/156802606776743084] [PMID: 16712492]
[http://dx.doi.org/10.1159/000356646] [PMID: 24401368]
[http://dx.doi.org/10.1093/hmg/10.12.1317] [PMID: 11406613]
[PMID: 25063079]
[http://dx.doi.org/10.1124/dmd.114.057141] [PMID: 24595682]
[http://dx.doi.org/10.1074/jbc.M309219200] [PMID: 14600149]
[http://dx.doi.org/10.1038/nrm1644] [PMID: 15852042]
[http://dx.doi.org/10.3389/fphys.2015.00040] [PMID: 25729367]
[http://dx.doi.org/10.1016/j.neurobiolaging.2016.12.015] [PMID: 28089352]
[http://dx.doi.org/10.1111/acel.12902] [PMID: 30706990]
[http://dx.doi.org/10.1111/jnc.13507] [PMID: 26710318]
[PMID: 25973041]
[http://dx.doi.org/10.18632/oncotarget.21177] [PMID: 29207665]
[http://dx.doi.org/10.1523/JNEUROSCI.5065-07.2008] [PMID: 18234899]
[http://dx.doi.org/10.1038/srep19946] [PMID: 26818210]
[http://dx.doi.org/10.1007/s12035-016-9965-4] [PMID: 27344331]
[http://dx.doi.org/10.1007/s12035-018-1295-2] [PMID: 30112629]
[http://dx.doi.org/10.1101/lm.026492.112] [PMID: 22904366]
[http://dx.doi.org/10.2174/1573406411666151030112140] [PMID: 26527155]
[http://dx.doi.org/10.3389/fnagi.2016.00013] [PMID: 26903857]
[http://dx.doi.org/10.1007/s00401-010-0756-0] [PMID: 20936480]
[http://dx.doi.org/10.3233/JAD-131463] [PMID: 24284365]
[http://dx.doi.org/10.1016/j.arr.2016.10.006] [PMID: 27825897]
[http://dx.doi.org/10.1016/S0531-5565(96)00036-8] [PMID: 9088907]
[http://dx.doi.org/10.1016/j.jns.2013.12.017] [PMID: 24423585]
[http://dx.doi.org/10.3389/fnbeh.2018.00092] [PMID: 29867393]
[http://dx.doi.org/10.15252/emmm.201606520] [PMID: 27485122]
[http://dx.doi.org/10.1016/S1474-4422(09)70299-6] [PMID: 20083042]
[http://dx.doi.org/10.2174/157015906776359577] [PMID: 18615127]
[http://dx.doi.org/10.2214/ajr.182.1.1820003] [PMID: 14684506]